Swissmedic

Summary report on authorisation – mRESVIA®

Marketing authorisation granted for mRESVIA®, an mRNA-based medicinal product.

Low obligation Product class Pharmaceuticals Switzerland Pharmaceuticals

22.06.2026

Dates and deadlines

Applies from

2026-06-22

Read the official source ↗

Published by Swissmedic. HealthSignal links to the original document; the summary above is extracted from the source text.